The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. [electronic resource]
- The Journal of biological chemistry Feb 2002
- 4989-98 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
0021-9258
10.1074/jbc.M107345200 doi
Anti-Arrhythmia Agents--pharmacology Astemizole--pharmacology Benzimidazoles--pharmacology Binding Sites Blotting, Western Cation Transport Proteins Cell Line Cell Membrane--metabolism Cisapride--pharmacology DNA-Binding Proteins Dose-Response Relationship, Drug ERG1 Potassium Channel Electrophysiology Ether-A-Go-Go Potassium Channels Gastrointestinal Agents--pharmacology Histamine H1 Antagonists--pharmacology Humans Inhibitory Concentration 50 Ions Long QT Syndrome--genetics Models, Chemical Mutagenesis, Site-Directed Mutation Patch-Clamp Techniques Piperidines--pharmacology Potassium Channels--chemistry Potassium Channels, Voltage-Gated Protein Folding Pyridines--pharmacology Quaternary Ammonium Compounds--chemistry Quinidine--pharmacology Structure-Activity Relationship Trans-Activators Transcriptional Regulator ERG